NeoChemo Preserves Rectum in Half of Patients With Rectal Cancer NeoChemo Preserves Rectum in Half of Patients With Rectal Cancer
Among patients with stage II or stage III rectal adenocarcinoma, organ preservation is achievable in up to half of patients who undergo total neoadjuvant chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 19, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Immunotherapy or Chemoimmunotherapy in NSCLC Neoadjuvant Immunotherapy or Chemoimmunotherapy in NSCLC
How do these treatments for non-small cell lung cancer compare? Is one more beneficial than the other?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 2, 2022 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Basel, 25 April 2022Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early...
Source: Roche Media News - April 25, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth in the first quarter of 2022
Group sales increase 11%1 at constant exchange rates (CER) and 10% in Swiss francsPharmaceuticals Divisionsales up 6%; continued strong sales of new medicines for severe diseases. Impact of biosimilars decreases as expected.Diagnostics Divisionsales grow 24% due to good momentum in base business and continued high demand for COVID-19 tests. After a strong first quarter, significant decline in COVID-19-related testing expected.Highlights in the first quarter:FDA approval of Vabysmo (severe eye diseases); CHMP recommends EU approval of Polivy combination (aggressive form of blood cancer), Tecentriq (early-stage non-small cel...
Source: Roche Investor Update - April 25, 2022 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Media News - April 22, 2022 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Investor Update - April 22, 2022 Category: Pharmaceuticals Source Type: news

AACR: Adding Nivolumab to Neoadjuvant Chemo Slows Resectable NSCLC
TUESDAY, April 12, 2022 -- Neoadjuvant nivolumab plus chemotherapy results in significantly longer event-free survival and increased pathological response among patients with resectable non-small cell lung cancer (NSCLC) compared with chemotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2022 Category: Pharmaceuticals Source Type: news

Preop Nivolumab Plus Chemo'a Quantum Leap' in NSCLC Therapy Preop Nivolumab Plus Chemo'a Quantum Leap' in NSCLC Therapy
Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non –small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 12, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Preop Nivoulmab Plus Chemo'a Quantum Leap' in NSCLC Therapy Preop Nivoulmab Plus Chemo'a Quantum Leap' in NSCLC Therapy
Further data from the pivotal Checkmate 816 trial continue to support the combination of nivolumab with chemotherapy in the neoadjuvant setting for patients with resectable non –small cell lung cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 12, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Nivolumab a 'New Standard' in Lung Cancer
(MedPage Today) -- NEW ORLEANS -- The addition of the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy substantially improved event-free survival (EFS) in patients with operable non-small cell lung cancer (NSCLC), the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 12, 2022 Category: Hematology Source Type: news

Chemo and RT Before Surgery Boosts Pancreatic Cancer Survival Chemo and RT Before Surgery Boosts Pancreatic Cancer Survival
Long-term results from the Dutch PREOPANC trial confirm that neoadjuvant chemoradiotherapy conveys a survival advantage to patients with resectable and borderline resectable pancreatic cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 10, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

U.S. Food and Drug Administration Approves Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Certain Adult Patients with Resectable Non-Small Cell Lung Cancer
Approval marks the first-and-only immunotherapy-based treatment for use before surgery for non-small cell lung cancer1 In the Phase 3 CheckMate -816 trial, Opdivo plus platinum-doublet chemotherapy significantly improved event-free survival and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 7, 2022 Category: Drugs & Pharmacology Source Type: news

FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC FDA Approves Neoadjuvant Nivolumab/Chemo for Early-Stage NSCLC
The pathologic complete response rate was 24% versus 2.2% with chemotherapy alone.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma Neoadjuvant Chemo New SOC Option in Urothelial Carcinoma
Neoadjuvant chemotherapy in the high-risk population demonstrated favorable pathologic responses, and was well tolerated.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 24, 2022 Category: Surgery Tags: Hematology-Oncology News Source Type: news